On March 13, Lifeward received shareholder approval to finalize a strategic partnership with Oramed. The partnership grants Lifeward access to up to $47 million in capital. Lifeward will integrate Oramed's POD™ oral delivery technology into its platform.
BioHarvest Sciences Inc. (NASDAQ: BHST) reported full-year 2025 revenue of $34.5 million, marking a 37% increase over the previous year. In the fourth quarter, the company posted a loss of $0.10 per share, outperforming the Zacks Consensus Estimate of a $0.11 loss. This performance reflects a significant…
Read the full storyBank of America has initiated coverage on MiniMed Group (NASDAQ: MMED) with a "Buy" rating and a price target of $27 per share. This target implies a significant upside potential of approximately 100% from the stock's current trading price of about $14. Analysts at the bank believe the diabetes management technology…
Minerva Neurosciences (Nasdaq: NERV) has officially commenced the screening of the first patient in its global Phase 3 clinical trial for roluperidone. This confirmatory study is designed to evaluate the drug's efficacy as a monotherapy for treating the negative symptoms of schizophrenia. The trial represents a…
BioPorto A/S has officially submitted its pre-submission package to the U.S. Food and Drug Administration (FDA) for its adult urine NGAL program. This regulatory milestone follows a successful analysis of the EPACRA AKI study, which provided critical data for determining clinical cut-off levels. The diagnostic program…
Gan & Lee Pharmaceuticals (SSE: 603087) announced that its investigative once-weekly basal insulin injection, GZR4, successfully met primary endpoints in two pivotal Phase 3 clinical trials. The trials, named SUPER-1 and SUPER-2, were designed to evaluate the efficacy and safety of the long-acting insulin compared to…
MAIA Biotechnology (NYSE American: MAIA) announced significant survival results from its ongoing Phase 2 THIO-101 clinical trial. The company reported that eight patients with non-small cell lung cancer (NSCLC) achieved overall survival exceeding two years during the study. These findings were presented at the…
LifeMD has officially launched a telehealth subscription program for Novo Nordisk's Wegovy, offering patients potential annual savings of up to $1,200 on GLP-1 therapies. This initiative comes at a critical juncture for Novo Nordisk (NVO), whose shares recently hit five-year lows prior to the announcement. Currently,…
Nuwellis (NUWE) reported that its pediatric segment contributed approximately 50% of its total U.S. revenue in 2025, supported by an operational network of 47 medical centers. Despite this strategic milestone, the company's stock has faced significant pressure, experiencing a 97% decline over the past year. While…
DeFi Development Corp. (Nasdaq: DFDV) has announced a massive 442% increase in revenue for the 2025 fiscal year. This significant growth was highlighted in the company's FY 2025 Shareholder Letter and Business Update released on March 30, 2026. The company distinguishes itself as the first U.S. public firm to adopt a…
Cyprium Therapeutics, a subsidiary of Fortress Biotech (FBIO), has successfully finalized the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The transaction generated gross proceeds of $205 million, marking a significant liquidity event for the company. Management characterized the deal as…
Kala Bio (KALA) has officially transitioned from a pre-revenue stage to a revenue-generating model following the deployment of its BIRA AI platform. The company confirmed that the platform is now live and operational within client-controlled environments, marking its entry into the revenue-generating AI infrastructure…
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the successful completion of treatment and follow-up for 18 participants in its Phase I/IIa clinical trial. The trial evaluates CMND-100, a non-hallucinogenic oral drug candidate designed to treat Alcohol Use Disorder (AUD). The study is conducted across multiple…
SeaStar Medical (ICU) has presented encouraging new data from its SAVE Registry regarding the QUELIMMUNE Selective Cytopheretic Device (SCD) therapy. The findings, showcased at the AKI & CRRT 2026 conference, highlight the safety and efficacy of the treatment in pediatric patients. Notably, the analysis revealed no…
BioRestorative Therapies announced positive blinded Phase 2 clinical trial results for its stem cell-based product, BRTX-100. The treatment targets chronic lumbar disc disease using hypoxic-cultured mesenchymal stem cells to improve patient outcomes. According to the reported data, 50% or more of patients achieved a…
Teva Pharmaceutical Industries (TEVA) announced that the U.S. FDA has approved PONLIMSI as a biosimilar to the reference product Prolia. In addition to this approval, the company received filing acceptances for its Xolair biosimilar candidate from both the FDA and the European Medicines Agency (EMA). These milestones…
Unity (NYSE: U) reported strong preliminary financial results for the first quarter, with revenue expected to reach between $505 million and $508 million, surpassing its previous guidance. The company projects Adjusted EBITDA to range from $130 million to $135 million, marking a substantial 58% year-over-year…
Zenas BioPharma (ZBIO), a clinical-stage biopharmaceutical company, has announced the commencement of concurrent public offerings of common stock and convertible senior notes due 2032. The company intends to utilize the proceeds from these offerings to fund the development and commercialization of its therapeutic…
Abbott Laboratories has finalized its acquisition of Exact Sciences in a deal valued at approximately $23 billion, marking a significant expansion into the cancer diagnostics market. This strategic move aligns with the company's broader focus on long-term chronic disease management and prevention. Simultaneously,…
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced it is in the advanced stages of evaluating the acquisition of a specialized contract research organization (CRO) to bolster its clinical development capabilities. The potential transaction is projected to contribute more than $20 million in annual revenue and…
Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare has successfully completed a series of robotic peripheral endovascular procedures using its LIBERTY Endovascular Robotic System. These procedures included the world's first robotic Prostatic Artery Embolization (PAE), marking a significant milestone in…
Tivic Health Systems (Nasdaq: TIVC) has entered into a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID). The collaboration focuses on conducting preclinical studies to evaluate the drug candidate Entolimod as a medical countermeasure. Specifically, the studies…
NextPlat Corp (NXPL) has announced a strategic collaboration with HealthWarehouse.com to enable medication fulfillment across all 50 U.S. states. This partnership marks a significant transition for the company, expanding its healthcare footprint from a regional focus in Florida to a nationwide scale. The new…
Emergent BioSolutions (NYSE: EBS) has announced securing new contracts and orders worth over $60 million for its smallpox medical countermeasure, VIGIV. The primary component is a $54 million contract from the U.S. government, exercised as an option under an existing 10-year agreement. This contract was awarded by the…
Brenmiller Energy Ltd. (BNRG) has officially transitioned to its commercialization phase, marking a significant milestone with the recognition of its first-ever revenue from a Thermal Energy Storage (TES) system sale. The company successfully delivered its flagship Tempo project, which represents the first…
Cibus, Inc. (Nasdaq: CBUS) has officially announced its intention to offer Class A common stock and pre-funded warrants through an underwritten public offering. As part of the proposal, the company expects to grant underwriters a 30-day option to acquire an additional 15% of the shares offered. The primary objective…
Bank of America has officially initiated coverage of Bicara Therapeutics (BCAX) with a 'Buy' rating and a price target of $35. The bank's positive outlook is primarily driven by the company's lead drug candidate, ficerafusp alfa (ficera). Analysts believe this oncology asset has the potential to become a new standard…
Corcept Therapeutics (NASDAQ: CORT) has received U.S. Food and Drug Administration (FDA) approval for its new drug Lifyorli (relacorilant). The treatment is characterized as a first-of-its-kind therapy specifically for platinum-resistant epithelial ovarian cancer when used in combination with nab-paclitaxel. Following…
Protalix BioTherapeutics (PLX) reported financial results for the full year 2025 that fell short of market expectations, but its optimistic outlook for 2026 has captured investor attention. The company issued robust revenue guidance for 2026 ranging between $78 million and $83 million, significantly exceeding current…
Radiopharm Theranostics (RAD) has announced encouraging interim results for its RAD 101 imaging agent, designed to diagnose recurrent brain metastases. The diagnostic tool targets fatty acid synthase (FASN) and is radiolabelled with Fluorine-18 to improve imaging precision in oncology. Following these successful…
Apimeds Pharmaceuticals US Inc. (APUS) has officially declared a material breach of its merger agreement by Inscobee Inc. and its subsidiary, Apimeds Inc. In response to the alleged violation, APUS is preparing to file an emergency legal action in the Delaware Court of Chancery to safeguard its contractual rights and…
NeuroSense Therapeutics (NRSN) has announced significant progress toward key regulatory milestones for its neurodegenerative disease pipeline. The company is currently strengthening its clinical data package to bolster upcoming regulatory submissions and support its therapeutic claims. Investors are closely watching…
20/20 BioLabs (Nasdaq: AIDX) has announced an exclusive U.S. technology license agreement with ROKIT Healthcare Inc. to advance its diagnostic capabilities. Under the deal, the company will integrate sophisticated Chronic Kidney Disease (CKD) prediction technology into its flagship OneTest for Longevity program. This…
Silexion Therapeutics (SLXN) has received regulatory clearance from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its lead candidate, SIL204. The study focuses on treating patients with locally advanced pancreatic cancer specifically driven by KRAS mutations, a segment with significant…
Matricelf (TASE: MTLF) has announced a strategic collaboration with Sheba Medical Center to support its inaugural first-in-human clinical trial. The partnership focuses on advancing regenerative medicine therapies specifically designed for spinal cord injuries. The clinical program involves the development of…
Gilead Sciences and Galapagos NV are in advanced negotiations to collaborate on a novel T Cell Engager program. The partnership aims to develop innovative therapies specifically targeting autoimmune diseases, strengthening both companies' positions in this vital sector. This strategic move follows Gilead's recent…
Apogee Therapeutics, Inc. (Nasdaq: APGE) has priced its upsized public offering of common stock at $70.00 per share, raising the total expected gross proceeds to $350 million from the previously announced $300 million. The offering consists of 5,000,000 shares of common stock, with underwriters granted a 30-day option…
William Blair has officially initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), issuing a positive outlook for the clinical-stage biotechnology firm. The investment bank highlighted the company's specialized focus on developing locally delivered, extended-release pharmaceutical products. Analysts at…
Embecta (EMBC) has announced a definitive agreement to acquire Owen Mumford for a total consideration of approximately $199.4 million. This strategic move is designed to diversify Embecta's medical device portfolio beyond its core focus on diabetes care. By integrating Owen Mumford's advanced technology, Embecta aims…
Gilead Sciences has entered into a definitive agreement to acquire the biotechnology firm Ouro Medicines for approximately $2 billion, confirming the deal previously in advanced discussions. The acquisition significantly bolsters Gilead's inflammation portfolio by adding OM336 (gamgertamig), a clinical-stage BCMAxCD3…
RenovoRx (RNXT) has announced the successful closing of an oversubscribed $10 million "at market" private placement. The offering saw significant interest from investors, resulting in demand that exceeded the initial offering size and reflecting strong market confidence. Management intends to utilize the net proceeds…
Linkers Industries Limited (NASDAQ: LNKS) has officially announced the pricing of its public offering, aiming to raise approximately $16 million in gross proceeds. The Malaysia-based company, which specializes in the manufacturing and supply of wire and cable harnesses, is conducting the offering on a 'best efforts'…
Wellgistics Health (NASDAQ: WGRX) has announced the signing of a non-binding Letter of Intent (LOI) to acquire Neuritek Therapeutics, a specialized neuroscience research organization. The proposed transaction is valued at approximately $105 million and is structured as an all-stock deal. This strategic move aims to…
ParaZero Technologies and Empery Digital, both listed on the NASDAQ, have announced separate registered direct offerings to raise a combined $29 million from institutional investors. ParaZero Technologies reached an agreement to sell approximately $4 million in ordinary shares and warrants at a price of $0.75 per…
Abbott (ABT) has officially announced the completion of its acquisition of Exact Sciences, marking a significant expansion of its global healthcare portfolio. The strategic move is designed to establish Abbott as a dominant leader in the rapidly growing cancer screening and diagnostics segments. By integrating Exact…
Alto Neuroscience has successfully secured $120 million in new funding to accelerate its clinical programs. The capital injection is specifically earmarked for the development and advancement of its neurological drug candidate, ALTO-207. This update was officially announced via a pre-market advisory from the New York…
Tarsus Pharmaceuticals (NASDAQ: TARS) announced that China's National Medical Products Administration (NMPA) has approved TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. The drug is already marketed in the United States under the brand name XDEMVY. This regulatory milestone in…
Victory Holdings (VMHG) has announced the signing of a definitive agreement to acquire Dunn & Groux Beverage Holdings, Inc. (DGBH). This strategic acquisition marks the company's official entry into the high-growth functional beverage market, currently valued at over $190 billion. Under the terms of the agreement,…
InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced promising preclinical data for its drug candidate INM-901, aimed at treating Alzheimer's disease. The study, conducted in collaboration with Stem Pharm, demonstrated the drug's effectiveness in reducing neuroinflammation within 3D human brain organoid models. This…
Lexicon Pharmaceuticals and Novo Nordisk have officially initiated a Phase 1 clinical trial for their novel drug candidate, LX9851. Following the announcement, Lexicon Pharmaceuticals (LXRX) shares saw a positive price increase as investors reacted to the clinical milestone. This first-in-class oral treatment is…